Usefulness of High-resolution Computed Tomography for Macrolide Therapy of Idiopathic Bronchiectasis

Zenya Saito1, *, Masahiro Yoshida1, Shota Uchiyama1, Saiko Nishioka1, Kentaro Tamura1, Nobumasa Tamura1
1 Division of Respiratory Diseases, Department of Internal Medicine, Atsugi City Hospital, Kanagawa, Japan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 806
Abstract HTML Views: 390
PDF Downloads: 286
ePub Downloads: 173
Total Views/Downloads: 1655
Unique Statistics:

Full-Text HTML Views: 264
Abstract HTML Views: 206
PDF Downloads: 182
ePub Downloads: 133
Total Views/Downloads: 785

Creative Commons License
© 2023 Saito et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Respiratory Medicine, Atsugi City Hospital, 1-16-36 Mizuhiki, Atsugi-shi, Kanagawa 243-8588, Japan; Tel: +81-46-221-1570; Fax: +81-46-222-7836; E-mail:



High-resolution computed tomography (HRCT) correlates with clinical symptoms, respiratory function, and quality of life in bronchiectasis.


We aimed to investigate the relationship between macrolide and acute exacerbation (AE) in idiopathic bronchiectasis classified by the Bronchiectasis Radiologically Indexed CT Score (BRICS).


We retrospectively reviewed the medical records of patients diagnosed with idiopathic bronchiectasis between April 2014 and December 2020 at a single hospital. Overall, 115 patients with idiopathic bronchiectasis were selected and divided into three groups, according to the BRICS. Each group was divided into subgroups with and without macrolide therapy, and the number of patients with AE in each group was retrospectively compared.


About 45, 48, and 22 patients were included in the mild, moderate, and severe groups, respectively. In the mild group, the subgroup with macrolide therapy had significantly fewer patients with single AE than those without macrolide ( P = 0.029). There was no significant difference in the moderate and severe groups ( P = 1.00 and 0.64, respectively). In the multiple AE, the subgroup with macrolide therapy had significantly fewer patients than those without macrolide therapy in the mild, moderate, and severe groups ( P = 0.024, 0.029, and 0.026, respectively).


HRCT severity assessment might be useful in predicting treatment efficacy in patients with idiopathic bronchiectasis without previous AEs. Further large-scale clinical trials are required on the usefulness of HRCT in the future.

Keywords: Bronchiectasis, Exacerbation, Respiratory disease, High-resolution computed tomography, Macrolide, Assessment.